Indication
Kawasaki disease
Kawasaki disease is an acute, self-limited systemic vasculitis primarily affecting medium-sized arteries, most notably the coronary arteries. Read more about Kawasaki disease
17 drugs 10 manufacturers
Drugs that treat it
Common Kawasaki disease therapies.
PRIVIGEN (immune globulin,gamma(IgG))
CARIMUNE NF NANOFILTERED (immune globulin,gamma(IgG))
GAMMAGARD S-D (immune globulin,gamm(IgG)/glycine/glucose/IgA 0 to 50 mcg/mL)
GAMMAGARD S-D (immune globulin,gamm(IgG)/glycine/glucose/IgA 0 to 50 mcg/mL)
GAMMAGARD S-D (IGA < 1 MCG/ML) (immune globulin,gamm(IgG)/glycine/glucose/IgA 0 to 50 mcg/mL)
YIMMUGO (immune globulin,gamma (IgG)-dira human)
GAMMAGARD LIQUID ERC (immune globulin,gamma (IgG)/glycine/IgA 0 to 50 mcg/mL)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonKawasaki disease is an acute, self-limited systemic vasculitis primarily affecting medium-sized arteries, most notably the coronary arteries.
It predominantly develops in infants and young children under five years of age and stands as a leading cause of acquired pediatric heart disease.
Clinically, it is characterized by prolonged high fever, bilateral nonexudative conjunctivitis, mucosal changes such as strawberry tongue and lip erythema, polymorphous rash, induration or erythema of the extremities with desquamation, and cervical lymphadenopathy.
Pathophysiologically, widespread vascular inflammation can weaken arterial wall architecture, predisposing affected individuals to coronary artery dilation, aneurysm formation, thrombosis, and subsequent myocardial ischemia.
- nih.gov
Kawasaki disease is an acute, self-limited systemic vasculitis primarily affecting medium-sized arteries, most notably the coronary arteries Pathophysiologically, widespread vascular inflammation can weaken arterial wall architecture, predisposing affected individuals to coronary artery dilation, aneurysm formation, thrombosis, and subsequent myocardial ischemia
- nih.gov
Kawasaki disease is an acute, self-limited systemic vasculitis primarily affecting medium-sized arteries, most notably the coronary arteries
- cdc.gov
It predominantly develops in infants and young children under five years of age and stands as a leading cause of acquired pediatric heart disease
- nih.gov
It predominantly develops in infants and young children under five years of age and stands as a leading cause of acquired pediatric heart disease Pathophysiologically, widespread vascular inflammation can weaken arterial wall architecture, predisposing affected individuals to coronary artery dilation, aneurysm formation, thrombosis, and subsequent myocardial ischemia
- cdc.gov
Clinically, it is characterized by prolonged high fever, bilateral nonexudative conjunctivitis, mucosal changes such as strawberry tongue and lip erythema, polymorphous rash, induration or erythema of the extremities with desquamation, and cervical lymphadenopathy
- cdc.gov
Clinically, it is characterized by prolonged high fever, bilateral nonexudative conjunctivitis, mucosal changes such as strawberry tongue and lip erythema, polymorphous rash, induration or erythema of the extremities with desquamation, and cervical lymphadenopathy
Personalize your experience
Follow Kawasaki disease and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.